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A B S T R A C T
The present work deals with the rational design and in vitro evaluation of vaginal tablets for focal delivery of
ﬂuconazole (FLZ) and itraconazol (ITZ). Drug loaded liposomes with and without D-alpha-tocopheryl poly-
ethylene glycol 1000 succinate (vit E TPGS) were prepared by direct sonication of the components and mixed
with albumin to obtain albusomes. Tablets were obtained by direct compression of the lyophilized cake. The
inﬂuence of vit E TPGS on size, zeta potential and entrapment eﬃciency (EE%) of liposomes and albusomes was
evaluated. Tablet swelling and drug release were studied by in vitro assays. Vit E TPGS neither aﬀected the zeta
potential nor the EE% of liposomes and albusomes, but aﬀected the liposomes size and the tablet disintegration
time. A rapid erosion was observed for the tablets with the highest content of vitamin, while a slow swelling for
those lacking the vitamin (swelling index=57.76 ± 13.51%). A faster drug release proﬁle was obtained for the
former compared to the latter. The in vitro assay showed that FLZ diﬀused and solved in the vaginal ﬂuid
simulant while ITZ remained into the albusomes, which slowly released ITZ-albumin complex and ITZ-loaded
liposomes, both suitable carriers for drug transport to deeper vaginal endothelium.
1. Introduction
Vulvovaginal candidiasis (VVC) aﬀects most women at least once in
their lifetime. The increasing incidence of diabetes, malignancy and
chemotherapy, and the widespread use of immunosuppressive drugs
and broad-spectrum antibiotics have all contributed to the rise of
Candida infections. The impact and morbidity of VVC and recurrent
VVC (RVVC) are well recognized and warrant continued eﬀorts toward
improving patient outcomes (Sobel, 2016). Conventional vaginal for-
mulations cannot maintain eﬀective drug concentration for prolonged
periods of time and therefore new vaginal formulations based on micro
or nanoparticles, largely focused in the human immunodeﬁciency virus
(HIV) proﬁlaxis have received increasing attention (Cunha-Reis et al.,
2016; Fetherston et al., 2013; Gupta et al., 2012; Notario-Pérez et al.,
2018). In addition, the vaginal route is being considered for systemic
drug delivery and innovative formulations are being designed to over-
come the physiological factors that hinder formulation retention and
drug absorption (Krogstad et al., 2014; Sawant and Khan, 2017). Li-
posomes are one type of nanocarriers which oﬀer several advantages
over other drug delivery systems for vaginal delivery (Patel et al.,
2018). Liposomes have been proposed for acyclovir (Pavelić et al.,
2005), resveratrol (Joraholmen et al., 2015) and curcumin (Berginc
et al., 2014) delivery at the vaginal mucosa. In these cases vesicles are
incorporated into a Carbopol® gel (acyclovir) or coated with chitosan
(resveratrol and curcumin) for mucoadhesion. Nevertheless, there is
currently a debate on whether mucoadhesiveness is advantageous for
improving drug delivery at the mucosal sites or disadvantageous (das
Neves et al., 2018, 2011). It was recently shown that non-adhesive
nanoparticles can penetrate human and mouse mucus. Polyethylene
glycol coated nanoparticles are able to reach deeper into the more
slowly cleared mucus layers increasing epithelial coverage and vaginal
retention as, compared to mucoadhesive nanoparticles (Joraholmen
et al., 2017; Lai et al., 2007; Yang et al., 2014). While mucoadhesive
nanoparticles aggregate and remain trapped within the mucus, Pluronic
F127-coated particles achieve a more uniform distribution and close
proximity to cervical tumour (Yang et al., 2014). Although vaginal
formulations for local release face fewer obstacles than systemic de-
livery, local release still requires a rational design for the vaginal
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